Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenelinkGNLKQ Days Payable is 519.55 as of Sep. 2013.
Genelink's average Accounts Payable for the
three
months ended in Sep. 2013 was $1.26 Mil. Genelink's Cost of Goods Sold for the
three
months ended in Sep. 2013 was $0.22 Mil.
Hence, Genelink's Days Payable for the
three
months ended in Sep. 2013 was 519.55.
The historical rank and industry rank for Genelink's Days Payable or its related term are showing as below:
GNLKQ's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.715 * Ranked among companies with meaningful Days Payable only.
Genelink's Days Payable
increased
from Sep. 2012 (208.01) to Sep. 2013 (519.55).
It may suggest that Genelinkdelayed paying its suppliers.
The historical data trend for Genelink's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNLKQ vs VITIF, HSTC, NTRR: Days Payable Comparison
For the Biotechnology subindustry, Genelink's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genelink Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genelink's Days Payable distribution charts can be found below:
* The bar in red indicates where Genelink's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Genelink's Days Payable for the fiscal year that ended in Dec. 2012 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genelink (GNLKQ) has a Days Payable of 519.55 as of Sep. 2013. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genelink and its competitors.
Is Genelink's Days Payable too high?
Genelink's current Days Payable is 519.55. The Biotechnology industry median Days Payable is 112.72. Genelink's value of 519.55 is 360.9% above this industry median.
How does Genelink's Days Payable compare to VITIF and HSTC?
Genelink's Days Payable of 519.55 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 112.72. Genelink's value of 519.55 is 360.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genelink's current Days Payable of 519.55 is 360.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genelink and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genelink's current Days Payable is 519.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genelink stock overvalued right now?
Genelink (GNLKQ) has a current Days Payable of 519.55. The current Days Payable is 519.55 and 360.9% above the Biotechnology industry median of 112.72. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Genelink (GNLKQ), the current Days Payable is 519.55 as of Sep. 2013. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genelink Inc is a genetics-based, personal healthcare firm that has developed DNA assessments measuring personal DNA tendencies. These small differences in DNA, called SNPs can indicate genetic variants, the protein products of which may not be performing at optimal levels and can be linked to aging and other wellness issues. The company's scientists use the DNA assessments information from each client to formulate products to optimize health and wellness within normal ranges. The company has a compilation of issued and pending patents that center on using DNA analysis for the purpose of customizing nutrition and skin care formulations for wellness and anti-aging.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNLKQ has been successfully added to your 
